Geneva, Feb. 13 -- International Clinical Trials Registry received information related to the study (ChiCTR2600118415) titled 'Effects of Cognitive Behavioral Therapy Combined with Targeted Drug Therapy on Negative Emotions and Quality of Life in Patients with Pulmonary Arterial Hypertension' on Feb. 5.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Handan First Hospital
Condition:
Pulmonary artery hypertension
Intervention:
Trial group:Targeted drug therapy(Ambrisentan 10mg once daily) and cognitive behavioral therapy once aweek
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-02-28
Target Sample Size: Trial group:30;Control group:30;
Countries of Recruitment:
China
To...